Vertex Pharmaceuticals (VRTX) income statement
NASDAQ · Healthcare · Biotechnology · 6,400 employees · CEO Reshma Kewalramani
- Price
- $558.88 +3.50%
- Market cap
- $142B
- Enterprise value
- $137B
- Last report
- Q2 '26 filed 2026-08-04
- Next report
- 2026-11-02 EPS est. $4.82
Vertex Pharmaceuticals (VRTX) reported revenue of $3.33B for Q2 '26 (+12.5% year on year), operating income of $1.25B (37.4% of revenue) and net income of $1.1B. Over the last four quarters revenue was $12.6B.
Income statement
| Income statement | Trend | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.48B | $2.52B | $2.69B | $2.65B | $2.77B | $2.91B | $2.77B | $2.96B | $3.08B | $3.23B | $2.99B | $3.33B | |
| Cost of revenue | $319M | $368M | $343M | $372M | $393M | $423M | $363M | $408M | $415M | $466M | $393M | $489M | |
| Gross profit | $2.16B | $2.15B | $2.34B | $2.27B | $2.38B | $2.49B | $2.41B | $2.56B | $2.66B | $2.76B | $2.59B | $2.84B | |
| Research & development | $862M | $1.35B | $866M | $5.42B | $876M | $999M | $980M | $978M | $1.03B | $974M | $962M | $994M | |
| Other operating expenses | $0 | -$560M | -$100K | $500K | $15.3M | $86.3M | $401M | $3.1M | -$1.9M | $0 | $700K | $21.8M | |
| Operating expenses | $1.13B | $1.16B | $1.21B | $5.79B | $1.26B | $1.46B | $1.78B | $1.41B | $1.48B | $1.46B | $1.46B | $1.6B | |
| Operating income | $1.04B | $989M | $1.14B | -$3.51B | $1.12B | $1.03B | $630M | $1.15B | $1.19B | $1.3B | $1.14B | $1.25B | |
| Interest income | $168M | $180M | $181M | $157M | $132M | $128M | $121M | $122M | $126M | $122M | $115M | $121M | |
| Interest expense | $10.9M | $10.6M | $10.4M | $9.9M | $7.5M | $2.8M | $3M | $3.7M | $3.3M | $3.3M | $0 | $0 | |
| Other non-operating income (gains on investments, FX ...) | -$152M | -$170M | -$150M | -$133M | -$115M | -$113M | -$103M | -$136M | -$116M | -$33.9M | -$115M | -$145M | |
| Total non-operating income | $141M | $159M | $140M | $124M | $108M | $111M | $100M | $132M | $113M | $30.6M | $115M | $145M | |
| Income before tax | $1.18B | $1.15B | $1.28B | -$3.39B | $1.22B | $1.14B | $730M | $1.28B | $1.3B | $1.33B | $1.25B | $1.39B | |
| Income tax | $144M | $179M | $180M | $202M | $179M | $224M | $84.1M | $250M | $216M | $140M | $222M | $292M | |
| Net income | $1.04B | $969M | $1.1B | -$3.59B | $1.05B | $913M | $646M | $1.03B | $1.08B | $1.19B | $1.03B | $1.1B | |
| EPS (basic) | $4.01 | $3.76 | $4.26 | -$13.92 | $4.05 | $3.55 | $2.52 | $4.02 | $4.24 | $4.69 | $4.06 | $4.33 | |
| EPS (diluted) | $3.97 | $3.71 | $4.21 | -$13.92 | $4.01 | $3.50 | $2.49 | $3.99 | $4.20 | $4.65 | $4.02 | $4.31 | |
| Shares (basic, weighted) | 258M | 258M | 258M | 258M | 258M | 258M | 257M | 257M | 256M | 254M | 254M | 254M | |
| Shares (diluted, weighted) | 261M | 261M | 261M | 258M | 261M | 261M | 260M | 259M | 258M | 256M | 256M | 256M | |
| Depreciation & amortization | $42.1M | $59M | $53.5M | $54M | $53.2M | $46.5M | $48.4M | $51.7M | $54M | $55.7M | $55.9M | $56.5M | |
| EBITDA | $1.23B | $1.22B | $1.34B | -$3.33B | $1.28B | $1.18B | $782M | $1.34B | $1.36B | $1.39B | $1.31B | $1.45B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7B | $2.49B | $3.05B | $4.16B | $6.21B | $7.57B | $8.93B | $9.87B | $11B | $12.1B | |
| Cost of revenue | $210M | $275M | $410M | $548M | $736M | $904M | $1.08B | $1.26B | $1.53B | $1.81B | |
| Gross profit | $1.49B | $2.21B | $2.64B | $3.62B | $5.47B | $6.67B | $7.85B | $8.61B | $9.49B | $10.3B | |
| Research & development | $1.05B | $1.32B | $1.42B | $1.75B | $1.83B | $3.05B | $2.66B | $3.16B | $3.63B | $3.75B | |
| Sales & marketing | $31.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| General & administrative | $401M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Other operating expenses | $4.13M | $0 | -$790K | $0 | $13.1M | $0 | -$57.5M | $476M | $4.63B | $0 | |
| Operating expenses | $1.48B | $1.82B | $1.97B | $2.41B | $2.61B | $3.89B | $3.54B | $4.78B | $9.72B | $5.51B | |
| Operating income | $9.94M | $123M | $635M | $1.2B | $2.86B | $2.78B | $4.31B | $3.83B | -$233M | $4.76B | |
| Interest income | $0 | $11.7M | $0 | $63.7M | $22.2M | $4.9M | $145M | $615M | $598M | $491M | |
| Interest expense | $81.4M | $69.3M | $34.1M | $58.5M | $58.2M | $61.5M | $54.8M | $44.1M | $30.6M | $13.3M | |
| Other non-operating income (gains on investments, FX ...) | -$4.13M | $69.6M | -$37.6M | -$256M | -$319M | -$9.8M | $20.2M | -$592M | -$512M | $104M | |
| Total non-operating income | -$77.3M | -$139M | -$34.9M | $197M | $261M | -$51.7M | -$75M | $548M | $481M | -$118M | |
| Income before tax | -$67.4M | -$15.7M | $600M | $1.39B | $3.12B | $2.73B | $4.23B | $4.38B | $249M | $4.64B | |
| Income tax | $16.7M | -$107M | -$1.49B | $218M | $405M | $388M | $910M | $760M | $784M | $690M | |
| Net income | -$112M | $263M | $2.1B | $1.18B | $2.71B | $2.34B | $3.32B | $3.62B | -$536M | $3.95B | |
| EPS (basic) | -$0.46 | $1.06 | $8.25 | $4.58 | $10.44 | $9.09 | $12.97 | $14.05 | -$2.08 | $15.46 | |
| EPS (diluted) | -$0.46 | $1.04 | $8.09 | $4.51 | $10.29 | $9.01 | $12.82 | $13.89 | -$2.08 | $15.32 | |
| Shares (basic, weighted) | 244M | 249M | 254M | 257M | 260M | 258M | 256M | 258M | 258M | 256M | |
| Shares (diluted, weighted) | 245M | 253M | 259M | 261M | 263M | 260M | 259M | 261M | 258M | 258M | |
| Depreciation & amortization | $61.4M | $61.4M | $72.4M | $107M | $110M | $126M | $148M | $181M | $207M | $210M | |
| EBITDA | $75.5M | $103M | $707M | $1.56B | $3.28B | $2.92B | $4.44B | $4.61B | $486M | $4.87B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-01